Phase II study of vemurafenib followed by ipilimumab in patients with previously untreated BRAF-mutated metastatic melanoma
Crossref DOI link: https://doi.org/10.1186/s40425-016-0148-7
Published Online: 2016-08-16
Published Print: 2016-12
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Amin, Asim
Lawson, David H.
Salama, April K.S.
Koon, Henry B.
Guthrie, Troy
Thomas, Sajeve S.
O’Day, Steven J.
Shaheen, Montaser F.
Zhang, Bin
Francis, Stephen
Hodi, F. Stephen
Funding for this research was provided by:
Bristol-Myers Squibb